122 related articles for article (PubMed ID: 27393958)
1. Effect of linker length and residues on the structure and stability of a fusion protein with malaria vaccine application.
Shamriz S; Ofoghi H; Moazami N
Comput Biol Med; 2016 Sep; 76():24-9. PubMed ID: 27393958
[TBL] [Abstract][Full Text] [Related]
2. Design, structure prediction and molecular dynamics simulation of a fusion construct containing malaria pre-erythrocytic vaccine candidate, PfCelTOS, and human interleukin 2 as adjuvant.
Shamriz S; Ofoghi H
BMC Bioinformatics; 2016 Feb; 17():71. PubMed ID: 26851942
[TBL] [Abstract][Full Text] [Related]
3. Solution structure of a Plasmodium falciparum AMA-1/MSP 1 chimeric protein vaccine candidate (PfCP-2.9) for malaria.
Peng H; Hu Y; Zhou A; Jin C; Pan W
Malar J; 2010 Mar; 9():76. PubMed ID: 20236549
[TBL] [Abstract][Full Text] [Related]
4. Heat-precipitation allows the efficient purification of a functional plant-derived malaria transmission-blocking vaccine candidate fusion protein.
Beiss V; Spiegel H; Boes A; Kapelski S; Scheuermayer M; Edgue G; Sack M; Fendel R; Reimann A; Schillberg S; Pradel G; Fischer R
Biotechnol Bioeng; 2015 Jul; 112(7):1297-305. PubMed ID: 25615702
[TBL] [Abstract][Full Text] [Related]
5. Malaria vaccine candidate antigen targeting the pre-erythrocytic stage of Plasmodium falciparum produced at high level in plants.
Voepel N; Boes A; Edgue G; Beiss V; Kapelski S; Reimann A; Schillberg S; Pradel G; Fendel R; Scheuermayer M; Spiegel H; Fischer R
Biotechnol J; 2014 Nov; 9(11):1435-45. PubMed ID: 25200253
[TBL] [Abstract][Full Text] [Related]
6. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
[TBL] [Abstract][Full Text] [Related]
7. Structural basis of antigenic escape of a malaria vaccine candidate.
Dutta S; Lee SY; Batchelor AH; Lanar DE
Proc Natl Acad Sci U S A; 2007 Jul; 104(30):12488-93. PubMed ID: 17636123
[TBL] [Abstract][Full Text] [Related]
8. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
[TBL] [Abstract][Full Text] [Related]
10. The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria.
Karch CP; Doll TAPF; Paulillo SM; Nebie I; Lanar DE; Corradin G; Burkhard P
J Nanobiotechnology; 2017 Sep; 15(1):62. PubMed ID: 28877692
[TBL] [Abstract][Full Text] [Related]
11. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a multi-stage, multi-subunit malaria vaccine candidate for the production in Pichia pastoris by the identification and removal of protease cleavage sites.
Spiegel H; Schinkel H; Kastilan R; Dahm P; Boes A; Scheuermayer M; Chudobová I; Maskus D; Fendel R; Schillberg S; Reimann A; Fischer R
Biotechnol Bioeng; 2015 Apr; 112(4):659-67. PubMed ID: 25335451
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
14. Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine.
Ripley Ballou W
Microbes Infect; 2007 May; 9(6):761-6. PubMed ID: 17412630
[TBL] [Abstract][Full Text] [Related]
15. Heterologous expression of the C-terminal antigenic domain of the malaria vaccine candidate Pfs48/45 in the green algae Chlamydomonas reinhardtii.
Jones CS; Luong T; Hannon M; Tran M; Gregory JA; Shen Z; Briggs SP; Mayfield SP
Appl Microbiol Biotechnol; 2013 Mar; 97(5):1987-95. PubMed ID: 22592550
[TBL] [Abstract][Full Text] [Related]
16. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS
PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691
[TBL] [Abstract][Full Text] [Related]
17. Improvement in yield and purity of a recombinant malaria vaccine candidate based on the receptor-binding domain of Plasmodium vivax Duffy binding protein by codon optimization.
Yazdani SS; Shakri AR; Pattnaik P; Rizvi MM; Chitnis CE
Biotechnol Lett; 2006 Jul; 28(14):1109-14. PubMed ID: 16794771
[TBL] [Abstract][Full Text] [Related]
18. Immune protection-inducing protein structures (IMPIPS) against malaria: the weapons needed for beating Odysseus.
Patarroyo ME; Patarroyo MA; Pabón L; Curtidor H; Poloche LA
Vaccine; 2015 Dec; 33(52):7525-37. PubMed ID: 26469723
[TBL] [Abstract][Full Text] [Related]
19. Effect of Linker Length and Flexibility on the Clostridium thermocellum Esterase Displayed on Bacillus subtilis Spores.
Chen H; Wu B; Zhang T; Jia J; Lu J; Chen Z; Ni Z; Tan T
Appl Biochem Biotechnol; 2017 May; 182(1):168-180. PubMed ID: 27933482
[TBL] [Abstract][Full Text] [Related]
20. Merozoite surface protein 2 of Plasmodium falciparum: expression, structure, dynamics, and fibril formation of the conserved N-terminal domain.
Low A; Chandrashekaran IR; Adda CG; Yao S; Sabo JK; Zhang X; Soetopo A; Anders RF; Norton RS
Biopolymers; 2007 Sep; 87(1):12-22. PubMed ID: 17516503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
